We read with great interest the article regarding the CRISP-PFO score for optimizing patient selection for patent foramen ovale closure [1]. While refining risk stratification in patients with a Risk of Paradoxical Embolism score ≥ 7 is necessary for precision medicine, several issues warrant further discussion.
